PC
CBIO

Polar Capital’s Crescent Biopharma CBIO Stock Holding History

Polar Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,476
Closed -$16.9M – 279
2018
Q2 		$16.9M Buy
10,476
+185
+2% +$318K 0.1% 168
2018
Q1 		$16.7M Buy
10,291
+3,498
+51% +$7.27M 0.17% 152
2017
Q4 		$11.4M Buy
+6,793
New +$8.98M 0.12% 158
2015
Q1 		– Sell
-160
Closed -$115K – 288
2014
Q4 		$115K Buy
+160
New +$125K ﹤0.01% 275

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Polar Capital's CBIO Position: Q3 2018 in Review

Polar Capital sold out of Crescent Biopharma (CBIO) in Q3 2018, closing a stake of 10,476 shares — an estimated $16.9M sold.

Polar Capital first reported a position in CBIO in Q4 2014 and held it in 4 quarters. The position peaked at $16.9M in Q2 2018. 85 funds tracked by Wall St. Rank hold CBIO as of Q3 2018.

  • Polar Capital reported no remaining Crescent Biopharma position as of Q3 2018 after selling out during the quarter.
  • Polar Capital sold 10,476 Crescent Biopharma shares in Q3 2018, an estimated $16.9M.
  • Polar Capital first reported a position in Crescent Biopharma in Q4 2014 and held it in 4 quarters.
  • Polar Capital's Crescent Biopharma position peaked at $16.9M in Q2 2018.
  • 85 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2018.

Based on Polar Capital's 13F filing for Q3 2018, filed 14 Nov 2018.